by Proxiva Peptides | Mar 6, 2026 | Research Guides
Ipamorelin vs Hexarelin: Selectivity and Sustainability Against Raw Potency Hexarelin and ipamorelin occupy opposite ends of the growth hormone-releasing peptide (GHRP) spectrum. Hexarelin is widely regarded as the most potent synthetic GHRP ever characterized,...
by Proxiva Peptides | Mar 6, 2026 | Research Guides
Ipamorelin vs GHRP-2: The Selectivity-Potency Trade-Off in Growth Hormone Research Among the growth hormone-releasing peptides (GHRPs), ipamorelin and GHRP-2 represent two distinct points along the selectivity-potency spectrum. Both peptides activate the growth...
by Proxiva Peptides | Mar 6, 2026 | Research Guides
Ipamorelin vs GHRP-6: How Selectivity Defines the Research Utility of Ghrelin Mimetics Ipamorelin and GHRP-6 both belong to the growth hormone-releasing peptide (GHRP) family and share a common primary target: the growth hormone secretagogue receptor type 1a...
by Proxiva Peptides | Mar 6, 2026 | Research Guides
CJC-1295 vs GHRP-2: Two Complementary Pathways in Growth Hormone Research The regulation of growth hormone (GH) secretion involves a complex interplay between stimulatory and inhibitory signals. Two of the most widely studied peptide classes in GH research—GHRH...
by Proxiva Peptides | Mar 6, 2026 | Research Guides
CJC-1295 vs GHRP-6: Understanding Two Distinct Pathways of Growth Hormone Modulation Growth hormone (GH) secretion is governed by two complementary signaling systems: the growth hormone-releasing hormone (GHRH) pathway and the ghrelin/growth hormone secretagogue...
